Market research
AVTE Aerovate Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 28 Apr 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 81.6668
- Dividend yield
- 0.0%
- Beta
- 0.95
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 81.6668
- Dividend yield
- 0.0%
- Beta
- 0.95
About
About Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Research context
Aerovate Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AVTE discussion.
5 years, 6 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Aerovate Therapeutics, Inc gets an overall score of 1/5.